Placeholder

Managing Marketing Under Medicare Part D

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 595. Categories: , , .

Product Description

Medicare Part D presents many opportunities, as well as challenges, for pharmaceutical marketers. As the industry adapts its marketing strategies for this evolving arena, transparency is a top priority. Brand teams also need to remain flexible and stay on top of emerging information and trends to best position their products…

Sidebars:
Patient-Assistance Programs: Picking Up the Pieces
Sound Bites from the Field:
Jill Balderson
, VP, Strategic Marketing, HealthEd. For more information, visit healthed.com.
Neil B. Krugman, Partner, Waller Lansden Dortch & Davis. For more information, visit wallerlaw.com.
John McCreedy, Executive VP, DestinationRx. For more information, visit destinationrx.com.
Stan Nowak, President and CEO, Silverlink. For more information, visit silverlink.com.
PharmaVOICE Reader Survey: Medicare Part D
Marketing Strategies Under Part D

Thought Leaders
Kevin Barnett. Senior VP, Campbell Alliance, Raleigh, N.C.; Campbell Alliance, a specialized management consulting firm serving the pharmaceutical and biotechnology industries, helps clients develop strategic and operational plans as well as improve the efficiency of their internal operations. For more information, visit campbellalliance.com.
Mike Dezelan. VP, Managed Markets, Serono Inc., Rockland, Mass.; Serono Inc., the U.S. affiliate of global biotechnology leader Serono, is focused on reproductive health, neurology, metabolism, and growth. For more information, visit seronousa.com.
Tony Farino. Pharmaceutical and Life Sciences Advisory Services Leader, PricewaterhouseCoopers LLP, Florham Park, N.J.; PricewaterhouseCoopers provides industry-focused assurance, tax, and advisory services for public and private clients. For more information, visit pwc.com.
Warren C. Levy. Chief Strategy Officer, Senior VP, Vox Medica, Philadelphia; Vox Medica is an independent healthcare communications company. For more information, visit voxmedica.com.
Larry Olson. Director of MMA Studies, GfK Market Measures, Princeton, N.J.; GfK Market Measures is a supplier of syndicated and custom-marketing research to the healthcare community and offers a series of studies specific to Medicare Part D. For more information, visit gfkmarketmeasures.com.
Anna Spencer. Partner, Sidley Austin LLP, Washington, D.C.; Sidley Austin is one of the world’s largest law firms with more than 1,600 lawyers and 15 offices in North America, Europe, and Asia. For more information,visit sidley.com.
Jeffrey L. Thomas. Managing Director, Ventiv Access Services, Somerset, N.J.; Ventiv Access Services is a unit of the Ventiv Commercial Services division of Ventiv Health, a leading provider of commercialization services to the global pharmaceutical and life-sciences industries. For more information, visit ventiv.com.
Joel Winterton. Owner, SET Enterprises, Phoenix; SET Enterprises is an independent management consultancy providing expertise in government pricing, Medicaid, and managed-care contracting to the pharmaceutical industry. For more information, e-mail joelwset@aol.com.
Stephen Zocchi. VP, Marketing, Model N, South San Francisco, Calif.; Model N provides revenue-management solutions based upon an integrated suite of applications for pricing, contracts, compliance, rebates, fees, and chargebacks optimized for the life-sciences industry. For more information, visit modeln.com.

FEEDBACK